Thermo Fisher Scientific is seeing “very, very significant demand” for its cold storage range as the race to get COVID-19 vaccines to market enters its closing stages.
UNICEF, the world’s largest single buyer of vaccines, is laying the groundwork for quick and efficient delivery of COVID-19 vaccines by purchasing and distributing more than half a billion single-dose syringes and other critical equipment in countries...
The progress in the race for a COVID-19 vaccine to date has been nothing short of phenomenal. But what can the industry learn from these achievements to inform vaccine development in the future?
The UK’s Vaccines Manufacturing & Innovation Centre (VMIC) announces that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the second of two GMP COVID-19 vaccine manufacturing suites located at Oxford Biomedica's...
Vaxxas has received a $22m US Government award to conduct a Phase 1 clinical study for its novel skin-patch vaccination platform. While the trial will use a pandemic influenza vaccine, Vaxxas is also investigating opportunities to use the technology against...
A project run by Gavi, the vaccine alliance, and the World Health Organization (WHO) to guarantee fair access to COVID-19 vaccines worldwide, has secured the backing of 64 higher income countries, with more set to sign up in the coming days.
Transporting a COVID-19 vaccine to 7.8 billion people around the world would fill 8,000 jumbo jets – illustrating the enormity of the distribution challenge. The International Air Transport Association (IATA) warns of potential capacity constraints,...
AstraZeneca has paused vaccination in all of its Oxford COVID-19 vaccine candidate trials globally, because of a potentially unexplained illness in one of the trials.
Preclinical proof of concept study concludes SAM vaccine candidate delivered through CNE can rapidly elicit protective immunity against ZIKV, with potential use for additional antigens.
Gavi establishes an Ebola vaccine program for the next five years, with a stockpile of vaccines created to be made available to low- and middle-income countries free of charge.
Merck announces that it has reallocated Gardasil from the US CDC stockpiles, as a surge in demand sees revenues from the vaccine rise 26% year-on-year.
Bavarian Nordic buys vaccines against rabies and tick-borne encephalitis from GlaxoSmithKline for €301m, with up to €495m more in milestones payments to follow.
Themis obtains an exclusive licence from Merck to develop vaccine candidates with an undisclosed indication, using its measles virus vector-based platform.
Once a neglected area of pharma research, companies are now investing heavily after several major commercial successes and with promising new avenues of research progressing.
Sanofi warns that the World Health Organization’s delayed strain selection will push back the date on which it delivers vaccines for the 2019-2020 flu season.
Vaccine research is still quite ‘empirical’ and there is a long way until it is turned into a rational, predictable modality, suggests director at the Bill and Melinda Gates Foundation.
The global vaccines market will develop at a rate of 6% through to 2025, driven by national need for immunization programs and expansion into different therapeutic areas.
SGS’ completed the ₤8.7m expansion of its large molecule testing facility in Glasgow and made room to increase its existing biosafety service and PCR platform capabilities.
